Submitted by Viatris
All countries face risks and potential health threats from an increasing range of factors including infectious diseases, food contamination and threats associated with climate change, extreme weather events and deforestation. Strengthening prevention and preparedness activities can pre-emptively avoid outbreaks, or contain them early on, reduce the possibility of conflicts becoming complex humanitarian health crises, and mitigate the impact of natural disasters.
The United Nations General Assembly (UNGA) 2023 High-level Meeting (HLM) on pandemic prevention, preparedness and response is a unique opportunity for global leaders to place health high on the political agenda and commit to bolstering resilient health systems for pandemic preparedness.
At Viatris, we are working with stakeholders across the globe to prepare for future pandemics. The work includes understanding how healthcare providers and systems can better help patients and respond to the needs of communities.
Building resilient health systems that can meet patient needs on an ongoing basis and respond rapidly and equitably to surges of infectious disease is critical. Our diverse efforts to advance this preparation include the following:
For more information, see our 2022 Sustainability Report.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn, Instagram and YouTube.
More from Viatris